{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T12:47:24Z","timestamp":1648644444666},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1997,7,1]],"date-time":"1997-07-01T00:00:00Z","timestamp":867715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[1997,7]]},"DOI":"10.1007\/bf02967063","type":"journal-article","created":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T04:28:03Z","timestamp":1223353683000},"page":"103-113","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of postoperative adjuvant therapy for stage ilia breast cancer: Futraful vs futraful+tamoxifen for er-positive patients and futraful vs futraful + adriamycin for er-negative breast cancer"],"prefix":"10.1007","volume":"4","author":[{"given":"Minoru","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osahiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaneo","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuharu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Sugimachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"19","key":"BF02967063_CR1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/87.19.1441","volume":"87","author":"A Goldhirsch","year":"1995","unstructured":"Goldhirsch A, Wood WC, Senn H,et al: Meeting highlights; International consensus panel on the treatment of primary breast cancer.JNCI 87(19):1441\u20131445, 1995.","journal-title":"JNCI"},{"issue":"l","key":"BF02967063_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02967368","volume":"l","author":"O Abe","year":"1994","unstructured":"Abe O: The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer; Meta-analysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC).Breast Cancer l(l):1\u20139, 1994.","journal-title":"Breast Cancer"},{"key":"BF02967063_CR3","first-page":"185","volume-title":"Current Diagnosis and Treatment of Breast Cancer","author":"T Yokoe","year":"1990","unstructured":"Yokoe T: Current Diagnosis and Treatment of Breast Cancer, Izuo Med, Nagai-Syoten, Tokyo, pp185\u2013195, 1990."},{"issue":"16","key":"BF02967063_CR4","first-page":"2720","volume":"21","author":"H Yamamoto","year":"1994","unstructured":"Yamamoto H: Controversies in the surgical, options for the patient with primary breast cancer.Jpn J Cancer Chemother 21(16):2720\u20132727, 1994.","journal-title":"Jpn J Cancer Chemother"},{"key":"BF02967063_CR5","first-page":"193","volume-title":"Chemotherapy of breast cancer; Current status. In: Meuson JC ed, Breast Cancer Trends in Research and Treatment","author":"SK Carter","year":"1976","unstructured":"Carter SK: Chemotherapy of breast cancer; Current status. In: Meuson JC ed, Breast Cancer Trends in Research and Treatment, Raven Press, New York, pp193\u2013215, 1976."},{"issue":"5","key":"BF02967063_CR6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J","volume":"41","author":"JM Bull","year":"1978","unstructured":"Bull JM, Tormey DC, Shou-Hua L,et al: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.Cancer 41(5): 1649\u20131657, 1978.","journal-title":"Cancer"},{"key":"BF02967063_CR7","first-page":"12","volume-title":"Worldwide Evidences 1985-1990","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1990","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group: Treatment of Early Breast Cancer, vol. 1; Worldwide Evidences 1985-1990, Oxford University Press, Oxford, pp12\u201318, 1990."},{"issue":"5","key":"BF02967063_CR8","first-page":"866","volume":"9","author":"O Abe","year":"1982","unstructured":"Abe O, Izuo M, Enomoto K,et al: Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer.Jpn J Cancer Chemother 9(5):866\u2013873, 1982.","journal-title":"Jpn J Cancer Chemother"},{"issue":"10","key":"BF02967063_CR9","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1002\/1097-0142(19921115)70:10<2475::AID-CNCR2820701014>3.0.CO;2-P","volume":"70","author":"M Toi","year":"1992","unstructured":"Toi M, Hattori T, Akagi M,et al: Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer.Cancer 70(10): 2475\u20132483, 1992.","journal-title":"Cancer"},{"issue":"8","key":"BF02967063_CR10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1990.8.8.1310","volume":"8","author":"F Boccardo","year":"1990","unstructured":"Boccardo F, Rubagotti A, Bruzzi P,et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients; Results of a multicentric Italian study.J Clin Oncol 8(8):1310\u20131320, 1990.","journal-title":"J Clin Oncol"},{"issue":"2","key":"BF02967063_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00000421-199404000-00003","volume":"17","author":"R Abe","year":"1994","unstructured":"Abe R, Tsuchiya A, Koie H,et al: A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan.Am J Clin Oncol 17(2):103\u2013108, 1994.","journal-title":"Am J Clin Oncol"},{"issue":"l","key":"BF02967063_CR12","first-page":"61","volume":"96","author":"CA Hubay","year":"1984","unstructured":"Hubay CA, Gordon NH, Crowe JP,et al: Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer; Seventy-two month follow-up.Surgery 96(l):61\u201372, 1984.","journal-title":"Surgery"},{"issue":"4","key":"BF02967063_CR13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1200\/JCO.1986.4.4.459","volume":"4","author":"B Fisher","year":"1986","unstructured":"Fisher B, Redmond C, Brown A,et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer; 5-Year results from the National Surgical Adjuvant Breast and Bowel Project Trial.J Clin Oncol 4(4): 459\u2013471, 1986.","journal-title":"J Clin Oncol"},{"key":"BF02967063_CR14","first-page":"337","volume-title":"Adjuvant Therapy of Cancer V","author":"M Kaufmann","year":"1987","unstructured":"Kaufmann M, Jonat W, Caffier H,et al: Adjuvant systemic risk adapted cytotoxic\u00b1 tamoxifen therapy in women with node positive breast cancer. In: Adjuvant Therapy of Cancer V, Grune & Stratton Inc, Orland, pp337\u2013346, 1987."},{"key":"BF02967063_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy.Lancet 339:1\u201315, 1992.","journal-title":"Lancet"},{"key":"BF02967063_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4613-1731-9_7","volume-title":"Endocrine Therapies in Breast and Prostate Cancer","author":"C Jordan","year":"1988","unstructured":"Jordan C: Antiestrogen therapy for breast cancer. In: Osboren K ed, Endocrine Therapies in Breast and Prostate Cancer, Kluwer Academic Publisher, Boston, pp97\u2013110, 1988."},{"issue":"5","key":"BF02967063_CR17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1989.7.5.572","volume":"7","author":"B Fisher","year":"1989","unstructured":"Fisher B, Redmond C, Wickerham DL,et al: Doxor- ubicin-containing regimens for the treatment of stage II breast cancer; The National Surgical Adjuvant Breast and Bowel Project experience.J Clin Oncol 7(5):572\u2013592, 1989.","journal-title":"J Clin Oncol"},{"issue":"7","key":"BF02967063_CR18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.1991.9.7.1124","volume":"19","author":"A Moliterni","year":"1991","unstructured":"Moliterni A, Bonadonna G, Valagussa P,et al: Cyclophosphamide, methotrexate and fluorouracil with and without doxorubicin in the adjuvant treatment resectable breast cancer with one to three positive axillary nodes.J Clin Oncol 19(7):1124\u20131130, 1991.","journal-title":"J Clin Oncol"},{"issue":"12","key":"BF02967063_CR19","first-page":"2523","volume":"10","author":"K Kubo","year":"1983","unstructured":"Kubo K, Abe O, Izuo M,et al: Clinical evaluation of adriamycin for advanced breast cancer (No. 3); A joint study by 26 institutes on the CAF and CMcF regimens.Jpn J Cancer Chemother 10(12):2523\u20132531, 1983.","journal-title":"Jpn J Cancer Chemother"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02967063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02967063\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02967063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T21:11:13Z","timestamp":1558473073000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02967063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["BF02967063"],"URL":"https:\/\/doi.org\/10.1007\/bf02967063","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}